Iovance Biotherapeutics Inc

IOVA

2.530USD

+0.170+7.20%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

Iovance Biotherapeutics Inc's Score

Industry at a Glance

Industry Ranking

94 / 392

Overall Ranking

221 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Iovance Biotherapeutics Inc Highlights

StrengthsRisks

Iovance Biotherapeutics, Inc. is a commercial biotechnology company. It is focused on developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. Its product, Amtagvi, is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. It is marketing Proleukin (aldesleukin), an interleukin-2 (IL-2) product used in the Amtagvi treatment regimen and in other applications. Amtagvi and Proleukin are part of a treatment regimen that includes lymphodepletion. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings and indications for solid tumor cancers. It also develops therapies, such as genetically modified TIL cell therapy and cytokines for use in the TIL cell therapy regimen.

Overvalued

The company’s latest PE is -2.13, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 245.96M shares, decreasing 23.82% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 784.00 shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.42.

Analyst Rating

Based on 12 analysts

Buy

Current Rating

8.400

Target Price

+244.26%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Iovance Biotherapeutics Inc is 7.78, ranking 78 out of 392 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 67.45M, representing a year-over-year increase of 15.20%, while its net profit experienced a year-over-year increase of 9.23%.

Score

Industry at a Glance

Previous score

7.78

Change

0



Financials

6.97

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.61

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

7.13

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.20

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Iovance Biotherapeutics Inc is 7.46, ranking 119 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -2.13, which is -35.98% below the recent high of -1.36 and -335.05% above the recent low of -9.25.

Score

Industry at a Glance

Previous score

7.46

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 94/392

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Iovance Biotherapeutics Inc is 7.17, ranking 308 out of 392 in the Biotechnology & Medical Research industry. The average price target is 9.00, with a high of 17.00 and a low of 1.50.

Score

Industry at a Glance

Previous score

7.17

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Iovance Biotherapeutics Inc is 6.48, ranking 235 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 2.97 and the support level at 2.15, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.16

Change

0.32

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Iovance Biotherapeutics Inc is 5.00, ranking 139 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 61.96%, representing a quarter-over-quarter decrease of 1.26%. The largest institutional shareholder is The Vanguard, holding a total of 27.12M shares, representing 6.83% of shares outstanding, with 17.73% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

MHR Fund Management LLC

28.97M

--

Quogue Capital L.L.C.

28.07M

--

The Vanguard Group, Inc.

Star Investors

24.01M

-4.07%

BlackRock Institutional Trust Company, N.A.

21.68M

+11.17%

State Street Investment Management (US)

13.31M

+34.57%

Invenomic Capital Management LP

10.54M

+27.09%

Long Focus Capital Management LLC

9.12M

-22.87%

Palo Alto Investors LP

7.62M

+122.15%

Geode Capital Management, L.L.C.

6.87M

+10.97%

BofA Global Research (US)

6.28M

+55.83%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Iovance Biotherapeutics Inc is 4.11, ranking 106 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.79. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.

Iovance Biotherapeutics Inc

IOVA

6.71 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.60 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.53 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ionis Pharmaceuticals Inc

IONS

8.38 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

IQVIA Holdings Inc

IQV

8.37 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.17 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment